GSK461364
- Product Name
- GSK461364
- CAS No.
- 929095-18-1
- Chemical Name
- GSK461364
- Synonyms
- CS-553;GSK4613;GSK461364;GSK-461364;GSK-461364A;GSK461364 USP/EP/BP;GSK461364(GSK-461364);GSK-461364; GSK-461364A;PLK1 inhibitor GS461364;PLK1 inhibitor GSK461364
- CBNumber
- CB62473747
- Molecular Formula
- C27H28F3N5O2S
- Formula Weight
- 543.6
- MOL File
- 929095-18-1.mol
GSK461364 Property
- Melting point:
- >150°C (dec.)
- Boiling point:
- 658.0±65.0 °C(Predicted)
- Density
- 1.39
- storage temp.
- Hygroscopic, -20°C Freezer, Under inert atmosphere
- solubility
- Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
- pka
- 15.16±0.50(Predicted)
- form
- Solid
- color
- Off-White to Light Beige
N-Bromosuccinimide Price
- Product number
- 18099
- Product name
- GSK461364
- Purity
- ≥95%
- Packaging
- 1mg
- Price
- $34
- Updated
- 2024/03/01
- Product number
- 18099
- Product name
- GSK461364
- Purity
- ≥95%
- Packaging
- 5mg
- Price
- $117
- Updated
- 2024/03/01
- Product number
- 18099
- Product name
- GSK461364
- Purity
- ≥95%
- Packaging
- 10mg
- Price
- $216
- Updated
- 2024/03/01
- Product number
- 18099
- Product name
- GSK461364
- Purity
- ≥95%
- Packaging
- 25mg
- Price
- $493
- Updated
- 2024/03/01
- Product number
- G797705
- Product name
- GSK461364
- Packaging
- 2.5mg
- Price
- $50
- Updated
- 2021/12/16
GSK461364 Chemical Properties,Usage,Production
Uses
GSK 461364 is a dose-dependant inhibitor of proliferating cancer cell lines as well as an apoptotic agent at higher dosage levels.
Definition
ChEBI: 5-[6-[(4-methyl-1-piperazinyl)methyl]-1-benzimidazolyl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide is a member of (trifluoromethyl)benzenes.
Biological Activity
gsk461364 is a potent and reversible atp competitive plk1 inhibitor. polo-like kinases (plk) are a family of serine threonine kinases that are critical regulators of dna damage response and cell cycle progression.
in vitro
gsk461364 showed at least 390-fold greater selectivity for plk1 than for plk2 and plk3 and 1,000-fold greater than for 48 other kinases. the drug showed antiproliferative activity against multiple (>120) tumor cell lines and potently inhibited the proliferation of greater than 83% and 91% of these cell lines [1].
in vivo
intraperitoneal administration of gsk461364 caused regression or tumor growth delay in different xenograft models. in vivo suppression of plk1 by using gsk461364 resulted in mitotic arrest with aberrant mitotic figures consisting of monopolar or collapsed mitotic spindles [1].
target
PLK1
References
[1] olmos d, barker d, sharma r, brunetto at, yap ta, taegtmeyer ab, barriuso j, medani h, degenhardt yy, allred aj, smith da, murray sc, lampkin ta, dar mm, wilson r, de bono js, blagden sp. phase i study of gsk461364, a specific and competitive polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. clin cancer res. 2011 may 15;17(10):3420-30.
GSK461364 Preparation Products And Raw materials
Raw materials
Preparation Products
GSK461364 Suppliers
View Lastest Price from GSK461364 manufacturers
- Product
- GSK-461364 929095-18-1
- Price
- US $1.00/g
- Min. Order
- 1g
- Purity
- 99%
- Supply Ability
- 1ton
- Release date
- 2020-01-10